UC San Diego Conducting First Clinical Trial For Cannabis As Migraine Treatment
As of May 19, 20 participants are enrolled in the clinical trial
While there are many US Food and Drug Administration (FDA)-approved treatments available for migraines, many people are already turning to cannabis as a form of alternative treatment. Now, Dr. Nathaniel Schuster and his team at the University of California San Diego are conducting the first-known randomized, double-blind, placebo-controlled clinical trial to look at cannabis as an effective treatment for acute migraines.
“Many patients who suffer from migraines have experienced them for many years but have never discussed them with their physicians. They are, rather, self-treating with various treatments, such as cannabis,” said Schuster, pain management specialist and headache neurologist at UC San Diego Health and investigator at the UC San Diego Center for Medicinal Cannabis Research. “Right now, when patients ask us if cannabis works for migraines, we do not have evidence-based data to answer that question.”
As of May 19, 20 participants are enrolled in the clinical trial. The ultimate goal is to enroll 90 participants who will be randomized to treat four separate migraine attacks with four different treatments; one treatment will be tetrahydrocannabinol (THC), one cannabidiol (CBD), one a combination of the two and a placebo. The products are all administered via a vaporizer.
To Read The Rest Of This Article On Culture Magazine, Click Here
